Complement TCC/sC5b-9 [Human] (CAT#: CB-P062-K) Datasheet

Kit

In all cases where determination of complement function is wanted, TCC levels can be very informative as a supplement to functional assessment of the three complement pathways. It reflects the historical in vivo activity of complement in a given sample. The complement system plays an essential role in chronic, autoimmune and infectious disease. There are three pathways of complement activation, namely the classical, the alternative and the lectin pathway. The soluble terminal complement complex is a product of the terminal pathway and can be a result from all three complement activation pathways. Since TCC reflects activation to the end of the final terminal pathway irrespective of the initial pathway involved, it is a particularly good candidate for general evaluation of complement activation. It is well-known that the complement system plays a key role in the development and amplification of the inflammatory process at the tissue level in various pathological conditions. Increased levels of TCC can be detected in for example hemolytic uremic syndrome (HUS), Systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). The complement system can also be activated by artificial surfaces, for example during hemodialysis or cardiopulmonary bypass, resulting in increased levels of TCC. TCC is also well suited for studies of complement activation by biomaterials in medical devices. TCC can like other activation products of complement be measured in assays using neo-epitope specific monoclonal antibodies. Neoepitopes are hidden in the native complement component and exposed after complement activation.

Complement TCC is an enzyme immunoassay for the semi-quantitative determination of soluble terminal complement complex (sTCC, also known as TCC or sC5b-9) in human EDTA plasma. For research use only, not for diagnostic procedures.

The assay is a colorimetric sandwich ELISA kit. Samples are diluted in assay diluent and 100µL diluted sample is transferred to the microtiter wells and incubated at room temperature for 60 minutes. During this first incubation TCC in the sample is captured by the anti-TCC monoclonal antibody, pre-coated on the surface of the microtiter wells. After washing to remove unbound material, a second horseradish peroxidase (HRP) labelled monoclonal antibody is added to detect the TCC bound to the well. After incubation for 30 minutes the wells are washed again and a substrate is added and incubated. The color development is stopped after 30 minutes and the color is measured in a spectrophotometer. The color is directly proportional to the amount of TCC bound to the well. The amount of TCC is determined by comparison to the color development of the calibrator samples.